Wollenberg A, Blauvelt A, Guttman‐Yassky E, et al. - In this study, the efficacy and safety of tralokinumab monotherapy were examined in adults with moderate‐to‐severe atopic dermatitis (AD) who had an inadequate response to topical treatments. Researchers randomized ECZTRA 1 and ECZTRA 2, adults with moderate‐to‐severe AD in a 3: 1 ratio to subcutaneous tralokinumab 300 mg every 2 weeks (Q2W), or placebo in two, 52‐week, randomized, double‐blind, placebo‐controlled, phase III trials. At 16 weeks, tralokinumab monotherapy was superior to the placebo of treatment and was well tolerated up to 52 weeks of treatment.